Skip to content
Bored Studies
RecruitingPhase 2

ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response

ACADIA Pharmaceuticals Inc. · NCT07284667

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–65 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 2
Target enrollment
153
US sites recruiting
24
Study start
November 14, 2025
Record last updated
October 5, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The goal of this clinical trial is to learn if ACP-211 can help treat adults with major depressive disorder (MDD) who have not improved with antidepressant therapy (ADT), including those with treatment resistant depression (TRD).

The main questions the study aims to answer are:

  • Does ACP-211 work better than a placebo (a look-alike capsule with no medicine) to reduce symptoms of depression?
  • What adverse events do participants have when taking ACP-211?

Being studied: ACP-211; Placebo

Conditions: Major Depressive Disorder (MDD); Depressive Disorder, Treatment-Resistant

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Adults ≥18 and ≤65 years of age
  • Provides written informed consent
  • Clinical diagnosis of MDD
  • History of inadequate response to at least two antidepressants, with at least one inadequate response documented during the current episode
  • Currently treated with an approved antidepressant at a stable dose prior to Screening
  • MADRS total score ≥28, CGI-S score ≥4 , and QIDS-SR16 score ≥16 at Screening and Baseline
  • Females of childbearing potential must have a negative pregnancy test and agree to use acceptable contraception; males must agree to use barrier protection and refrain from sperm donation

Exclusion Criteria

  • Current diagnosis of certain personality disorders or persistent depressive disorder
  • Recent substance use disorders, excluding caffeine or nicotine
  • Active suicidal risk or recent suicidal attempt
  • History of schizophrenia, psychotic disorders, bipolar disorder, or MDD with psychotic features
  • Current treatment requirement for PTSD, acute stress disorder, panic disorder, or OCD
  • History of neuroleptic malignant syndrome, serotonin syndrome, or epilepsy (except single febrile seizure in infancy)
  • Allergy or sensitivity to ketamine or esketamine
  • Significant cardiovascular disease
  • Positive history of hepatitis B, hepatitis C, or HIV infection
  • Unstable diabetes or uncontrolled medical conditions
  • Positive urine drug test for an illicit drug or cannabis
  • Received neuromodulation therapies (ECT, TMS, VNS, DBS) in the current depressive episode
  • Recent initiation or change in psychotherapy

Additional inclusion/exclusion criteria apply. Participants will be evaluated at Screening to ensure that all criteria for study participation are met.

Recruiting US locations

Study contacts (from the official record)

  • Sandy Filosi · +1(609) 250-6920 · sfilosi@ACADIA-Pharm.com
  • Lori Lykens · +1(609) 250-6917 · lori.lykens@acadia-pharm.com
All mental health studies in California →
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate… (NCT07284667) | Bored Studies